生物制剂联合传统系统药物或光疗治疗银屑病的真实世界数据:PSONET登记研究
该研究基于五个PSONET登记库,分析9922个生物制剂治疗周期中联合治疗的使用频率、人口学特征、治疗特征及药物生存率。结果显示9.9%为联合治疗,其中72.9%联用甲氨蝶呤,不同登记库间联合治疗类型和频率差异显著,且各生物制剂联合甲氨蝶呤的一年生存率无一致优势。
要点
- 生物制剂联合治疗占9.9%,甲氨蝶呤是最常用联用药物(72.9%)。
- 联合治疗患者多为病情严重且病程较长者,各登记库间特征存在差异。
- 各生物制剂联合甲氨蝶呤的一年生存率无一致优势,地理差异明显。
核心结论
- 甲氨蝶呤是生物制剂治疗中最常用的联合治疗药物,联合治疗选择及持续性存在广泛地理差异。
研究设计与样本
- 基于五个PSONET登记库的回顾性研究,共纳入9922个生物制剂治疗周期。
主要发现
- 982个(9.9%)治疗周期为联合治疗,其中72.9%联用甲氨蝶呤,25.3%联用UVB、阿维A或环孢素,1.8%联用PUVA、富马酸或第二种生物制剂。
- 依那西普、阿达木单抗、英夫利西单抗和乌司奴单抗联合甲氨蝶呤的一年生存率范围分别为43-92%、28-83%、65-87%和53-77%,无一致优势。
- 联合甲氨蝶呤、阿维A或环孢素的最长生存时间分别为103、78和34个月。
关键数值与推荐
- 联合治疗定义为生物制剂与传统系统药物或光疗同时使用。
- 药物生存率计算为治疗一年后的持续使用比例。
临床怎么用
- 真实世界中生物制剂联合治疗常见,甲氨蝶呤为主要联用药物,但选择与持续性因地区而异。
- 联合治疗多用于病情严重且病程长的患者,需根据地区实践和患者特征个体化决策。
局限性
- 各登记库间联合治疗类型和频率差异大,可能存在选择偏倚。
- 观察性数据无法确定联合治疗是否优于生物制剂单药治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes. OBJECTIVE: To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice. METHODS: We collected data on frequency of use, demographics, treatment characteristics and drug survival of biologics combined with conventional systemic agents or phototherapy in five PSONET registries. RESULTS: Of 9922 biologic treatment cycles, 982 (9.9%) were identified as combination treatment. 72.9% of treatment cycles concerned concomitant use of methotrexate, 25.3% concerned concomitant UVB therapy, acitretin or cyclosporin and 1.8% concerned combined treatment with PUVA, fumaric acids or a second biologic. Substantial variation was detected in type and frequency of combination treatments prescribed across registries. Patients initiated on combined treatment had generally severe disease and were affected with psoriasis for many years. The extent to which patients had been priory treated with biologic monotherapy and the proportion of patients affected with psoriatic arthritis differed between registries. Survival rates for etanercept, adalimumab, infliximab and ustekinumab with methotrexate ranged between 43 and 92%, 28 and 83%, 65 and 87% and 53 and 77%, respectively, across registries after one year with no consistent superior survival for a particular biologic. Longest survival on a biologic combined with methotrexate, acitretin or cyclosporin was 103, 78 and 34 months, respectively. CONCLUSION: Methotrexate was the most commonly used concomitant treatment for patients on a biologic. Wide geographical variations in treatment selection and persistence of combination treatment exist. Data derived from ongoing studies may help to determine whether combined treatment is superior to biologic monotherapy.
引用
- Busard CI, Cohen AD, Wolf P, et al. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. J Eur Acad Dermatol Venereol. 2017. PMID: 28898541. doi:10.1111/jdv.14583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。